Announcing the launch of Breakthroughs Today, Cures Tomorrow, our 20th anniversary campaign!
NETRF, in partnership with the North American Neuroendocrine Tumor Society (NANETS), is pleased to announce that Iacovos Michael, PhD, Scientist at Sunnybrook Research Institute and
Positive results are reported from the Phase 3 CABINET trial evaluating the drug cabozantinib in advanced neuroendocrine tumors. Interim data shows significant improvement in progression-free
In December 2022, four neighborhood girls from Libertyville, Il, gathered to support cancer research for the Neuroendocrine Tumor Research Foundation with a “Cookies for Cancer”
NETRF’s impact on neuroendocrine cancer research was evident at the 20th Annual European Neuroendocrine Tumor Society (ENETS) Conference, held March 22-24 in Vienna. The ENETS
A key tenet of NETRF’s mission is to help NET patients navigate the challenges of living with NET cancer. Participating in a clinical trial can
We are very grateful to Buckeye Cable Arts Network for allowing us to promote and share this wonderful story reporter Fayth Atkins produced about NET
NET patient, oncologist, and NETRF Board Member Mark Lewis, MD, is a native Scotsman who moved to Austin, TX as a young man when his
[BOSTON, MA, February 16, 2023–] The Neuroendocrine Tumor Research Foundation (NETRF) today announced its annual slate of neuroendocrine tumor (NET) research funding awards. The 12
The Cancer Moonshot’s success relies on ‘collaborative oncology.’ Just last month, the Neuroendocrine Tumor Research Foundation (NETRF) hosted our first in-person/hybrid research symposium since going
The Neuroendocrine Tumor Research Foundation elected Todd Gillman as President of its Board of Directors at the January 2022 meeting. Gillman replaces longtime president Joseph Li, MD.